QTc prolongation and/or oncology drug development: Who's in danger?

European Journal of Cancer

Volumn 44, Issue 4, 2008, Pages 486-487

  de Jonge, Maja ^a   Verweij, Jaap ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; PACLITAXEL;

ARTICLE; BRADYCARDIA; CARDIOTOXICITY; DRUG EFFICACY; HEART FAILURE; HUMAN; ONCOLOGY; PATIENT MONITORING; PRIORITY JOURNAL; QT PROLONGATION; RISK BENEFIT ANALYSIS;

EID: 40449088851     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.01.013     Document Type: Note

References (12)

1. Food and Drug Administration International conference on harmonisation; Guidance on E14 - The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs Fed Regist 70 2005 61134 61135
2. R. Kurzrock R.S. Benjamin Risks and benefits of phase 1 oncology trials, revisited N Engl J Med 352 2005 930 932
3. M.L. Telli S.A. Hunt R.W. Carlson Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility J Clin Oncol 25 2007 3525 3533
4. E.A. Perez Paclitaxel and cardiotoxicity J Clin Oncol 16 1998 3481 3482
5. G. Curigliano G. Spitaleri H. Fingert Drug-induced QTc interval prolongation: A proposal toward an efficient and safe anticancer drug development Eur J Cancer 44 2008 494 500
6. J. Morganroth Cardiac repolarization and the safety of new drugs defined by electrocardiography Clin Pharmacol Ther 81 2007 108 113
7. N. Sarapa X. Huang H. Fingert Risk management and eligibility criteria for QTc assessment in patients with advanced cancer Proc Amer Soc Clin Oncol 23 2005 203s (abstract 3047)
8. M. Varterasian M. Meyer H. Fingert Baseline heart rate-corrected QT and eligibility for clinical trials in oncology J Clin Oncol 21 2003 3378 3379
9. H. Fingert M. Varterasian Safety biomarkers and the clinical development of oncology therapeutics: Considerations for cardiovascular safety and risk management The AAPS Journal 8 2006 E89 E94
10. M.M. Cooney T. Radivoyevitch A. Dowlate Cardiovascular safety profile of Combretastatin A4 phosphate in a single-dose phase I study in patients with advanced cancer Clin Cancer Res 10 2004 96 100
11. M. Varterasian H. Fingert M. Agin Consideration of QT/QTc interval data in a phase I study in patients with advanced cancer Clin Cancer Res 10 2004 5967 5970
12. P. Honig Benefit and risk assessment in drug development and utilization: A role for clinical pharmacology Clin Pharmacol Ther 82 2007 109 112